Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VIRX
DateTimeSourceHeadlineSymbolCompany
01/06/202406:46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
30/05/202409:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
18/05/202406:05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
17/05/202406:26Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/05/202406:23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
15/05/202406:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
14/05/202421:00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
10/05/202407:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
10/05/202406:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
10/05/202406:05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
08/05/202406:05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
15/04/202422:00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
01/04/202423:30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
08/03/202409:04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
08/03/202408:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
08/03/202408:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
08/03/202408:05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
01/03/202400:00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
28/02/202412:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202411:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
28/02/202411:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/02/202413:04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
07/02/202408:05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
05/01/202400:00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
13/12/202300:00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
05/12/202308:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
05/12/202300:30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
29/11/202311:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
29/11/202311:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
18/11/202309:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

Your Recent History

Delayed Upgrade Clock